Fast and Full-Scale Multipass Membrane Protein-Specific Antibody Optimization Workflow at ImmunoPrecise Antibodies

Monoclonal antibodies (mAbs) are part of an important and growing class of biopharmaceuticals used to treat cancer and other human pathologies such as autoimmune, infectious and metabolic diseases. The clinical application of mAbs is significantly accelerated by advances in molecular engineering and antibody humanization, combined with the implementation of powerful screening technologies that allow for rapid identification of lead candidates. The growing need for discovery and isolation of new mAbs against more complex target antigens - such as multipass transmembrane proteins - requires advancements in high-throughput screening methods.

In this application note, we show how ImmunoPrecise Antibodies apply the iQue^® advanced flow cytometry platform at various stages of their engineering process, allowing the selection of therapeutically relevant, high-quality and low-risk antibodies in less time.